Preimplantation Genetic Testing Medical Services in China

Preimplantation Genetic Testing (PGT) is a specialized laboratory procedure performed during in vitro fertilization (IVF) to analyze embryos for genetic abnormalities prior to uterine transfer. It is not a disease but a diagnostic and preventive reproductive technology used within reproductive medicine to enhance the likelihood of a healthy pregnancy and reduce the risk of transmitting inheritable genetic disorders. PGT encompasses three primary subtypes: PGT-A (aneuploidy screening), which detects abnormal chromosome numbers (e.g., trisomy 21); PGT-M (monogenic/single-gene disorders), which identifies specific pathogenic variants linked to conditions such as cystic fibrosis, spinal muscular atrophy, or Huntington’s disease; and PGT-SR (structural rearrangements), designed for carriers of balanced chromosomal translocations or inversions. Pathogenesis underlying the need for PGT lies in gametogenesis errors—especially maternal meiotic nondisjunction—and de novo or inherited germline mutations. These errors increase with advancing maternal age, particularly after 35, and are also associated with recurrent pregnancy loss, repeated IVF implantation failure, severe male factor infertility, and known familial monogenic disease carriers. Epidemiologically, aneuploidy affects ~30–60% of human blastocysts, rising sharply with maternal age; approximately 1 in 200 live births carries a clinically significant monogenic disorder, and ~0.5–1% of couples undergoing IVF have an indication for PGT-M or PGT-SR. Key risk factors include advanced maternal age (>35 years), parental balanced chromosomal rearrangements, prior child or pregnancy affected by a genetic condition, history of ≥2 unexplained miscarriages, and multiple failed IVF cycles. While PGT itself carries no direct physical symptoms or morbidity, its clinical context profoundly impacts quality of life: patients often experience significant emotional distress—including anxiety, grief, guilt, and decisional burden—related to fertility challenges, ethical dilemmas around embryo selection/discard, financial strain, and prolonged treatment timelines. Psychosocial support, genetic counseling, and shared decision-making are integral to mitigating these impacts. Importantly, PGT does not guarantee pregnancy or eliminate all genetic risks—it cannot detect polygenic disorders, mosaicism below detection thresholds, or de novo mutations occurring post-biopsy. Its success depends on IVF efficacy, embryology expertise, and comprehensive pretest genetic counseling to define appropriate indications, limitations, and alternatives.

Preimplantation Genetic Testing (PGT) is not a disease or condition but rather an assisted reproductive technology (ART) procedure performed during in vitro fertilization (IVF) to analyze embryos for genetic abnormalities prior to uterine transfer. Its clinical application is driven by specific medical indications—namely, the presence or elevated risk of inheritable genetic disorders, chromosomal imbalances, or recurrent reproductive failure. Common causes prompting PGT referral include advanced maternal age (≥35 years), which correlates with increased meiotic errors and higher rates of embryonic aneuploidy; recurrent pregnancy loss (≥2–3 clinically recognized miscarriages), often attributable to parental balanced chromosomal rearrangements (e.g., Robertsonian or reciprocal translocations) or de novo embryonic aneuploidy; and recurrent implantation failure (≥3 failed transfers of morphologically high-grade embryos), where undetected chromosomal mosaicism or structural rearrangements may impair endometrial receptivity or early development. A significant proportion of cases stem from known monogenic disorders—such as cystic fibrosis, spinal muscular atrophy, Huntington disease, or hereditary BRCA1/2-related cancer syndromes—where one or both partners are confirmed carriers or affected individuals. Triggers for initiating PGT typically involve diagnostic confirmation via carrier screening, karyotyping, or molecular genetic testing in either partner; a documented history of an affected child; or identification of abnormal prenatal findings (e.g., ultrasound anomalies or positive non-invasive prenatal screening) in prior pregnancies. Risk factors encompass both biological and procedural domains: biologically, advanced paternal age (>40–45 years) contributes to increased de novo point mutations, particularly in autosomal dominant conditions; parental gonadal mosaicism may lead peripheral blood karyotypes; and diminished ovarian reserve (indicated by low AMH or elevated FSH) is associated with poorer oocyte quality and higher aneuploidy rates. Genetically, pathogenic variants in genes involved in DNA repair (e.g., BRCA1, MSH2, MLH1), meiotic recombination (e.g., SYCP3, STAG3), or chromosome segregation (e.g., BUB1B, CENPE) predispose to gametogenic errors and embryo aneuploidy. Balanced structural rearrangements carried by either parent confer up to 50% risk of unbalanced karyotypes in offspring, necessitating PGT for structural rearrangements (PGT-SR). Environmental factors play an indirect yet modifiable role: chronic exposure to tobacco smoke, heavy alcohol use, and occupational toxins (e.g., benzene, pesticides, ionizing radiation) has been associated with increased sperm DNA fragmentation and oocyte mitochondrial dysfunction, potentially elevating baseline aneuploidy and mosaicism rates. Obesity (BMI ≥30 kg/m²) induces systemic inflammation and oxidative stress, impairing folliculogenesis and spindle assembly; similarly, uncontrolled diabetes and thyroid dysfunction disrupt hormonal homeostasis critical for oocyte maturation and embryo genomic stability. Iatrogenic factors—including suboptimal ovarian stimulation protocols, prolonged in vitro culture, and substandard laboratory conditions (e.g., pH/osmolarity fluctuations, volatile organic compound exposure)—may exacerbate epigenetic instability or mitotic errors post-fertilization. Importantly, while PGT improves selection efficiency, it does not eliminate all genetic risks: limitations include technical constraints (e.g., inability to detect polyploidy, small copy-number variants <10–20 Mb, or triplet repeat expansions without specialized assays), embryonic mosaicism leading to false-negative or false-positive results, and the inherent biological constraint that PGT assesses only trophectoderm biopsy samples—not the inner cell mass—and cannot predict polygenic or multifactorial disorders (e.g., schizophrenia, type 2 diabetes). Therefore, comprehensive pretest genetic counseling, appropriate test selection (PGT-A, PGT-M, or PGT-SR), and integration with broader reproductive and medical evaluation remain essential to optimize outcomes and mitigate residual risks.

Preimplantation Genetic Testing (PGT) is not a clinical condition and therefore does not produce symptoms—neither early, typical, accompanying, nor complications—in the patient. It is an elective, laboratory-based diagnostic procedure performed during in vitro fertilization (IVF) to analyze embryos for chromosomal abnormalities or monogenic disorders prior to uterine transfer. As such, PGT itself is asymptomatic; any symptoms experienced by patients undergoing PGT are attributable to the underlying fertility treatment protocol (e.g., ovarian stimulation, oocyte retrieval, embryo transfer), not to the genetic testing process. This distinction is critical for accurate clinical interpretation and patient counseling.

Early symptoms associated with PGT cycles arise exclusively from controlled ovarian hyperstimulation (COH). These may include abdominal bloating, mild pelvic discomfort, breast tenderness, mood lability, and transient headache—typically emerging 5–10 days after initiation of gonadotropin therapy. Patients may also report transient nausea or fatigue secondary to exogenous hormone exposure (e.g., estradiol, progesterone, GnRH analogues). Importantly, these manifestations reflect pharmacologic effects—not pathophysiologic consequences of PGT—and resolve spontaneously upon cessation of hormonal support.

Typical symptoms during the PGT workflow are procedural rather than biological. Following transvaginal ultrasound-guided oocyte retrieval, patients commonly experience mild to moderate cramping (resembling menstrual pain), light vaginal spotting, and transient abdominal pressure lasting <48 hours. Post-retrieval, patients may report transient shoulder tip pain due to diaphragmatic irritation from residual intra-abdominal CO2 used during laparoscopic monitoring (though rare in modern transvaginal retrieval). During embryo biopsy—performed on day 3 (cleavage-stage) or, more commonly, day 5–6 (blastocyst-stage)—no patient-perceived symptoms occur, as the procedure is conducted entirely in vitro under microscopic guidance without patient involvement or sensation.

Accompanying symptoms relate to the broader IVF-PGT cycle context. Patients frequently report sleep disturbance, anxiety, and anticipatory stress linked to treatment timelines, financial burden, and uncertainty regarding embryo viability and genetic status. Hormonally mediated side effects may include constipation (progesterone-induced smooth muscle relaxation), mild edema (estradiol-mediated sodium retention), and increased vaginal discharge (estrogen-dominant cervical mucus changes). In some cases, patients develop mild ovarian hyperstimulation syndrome (OHSS)—characterized by abdominal distension, nausea, oliguria, and weight gain—but this is a complication of COH, not PGT. No symptom correlates directly with the molecular analysis (e.g., next-generation sequencing, polymerase chain reaction, or microarray) performed on biopsied trophectoderm cells.

Complications of PGT are procedural and embryological—not clinical—by nature. The primary risks involve embryo damage during biopsy (estimated incidence <0.5% per biopsied blastocyst), leading to embryo non-viability or inability to yield diagnostic DNA. Technical failure—including amplification failure, allele dropout (ADO), or inconclusive results—occurs in ~2–5% of tested embryos, necessitating re-biopsy (if viable) or transfer of untested embryos. There is no evidence that trophectoderm biopsy adversely affects live birth rates or neonatal outcomes when performed by experienced embryologists; however, theoretical concerns regarding placental mosaicism discordance persist. Critically, PGT does not cause maternal infection, hemorrhage, thromboembolism, or endocrine dysfunction—these complications, if observed, stem from concurrent IVF procedures or preexisting comorbidities.

Diagnosis of genetic conditions via PGT is achieved exclusively through laboratory methodologies—not clinical assessment. Standard techniques include: (1) PGT-A (aneuploidy screening) using comprehensive chromosome screening (CCS) via NGS or SNP-array to detect whole-chromosome gains/losses; (2) PGT-M (monogenic disorder testing) employing PCR-based haplotyping (e.g., Karyomapping or PG-Seq) with parental and reference samples to identify disease-causing variants; and (3) PGT-SR (structural rearrangements) utilizing breakpoint-spanning probes or NGS-based copy-number and structural variant detection. All analyses require prior validation of assay specificity, sensitivity (>98%), and limit of detection. Diagnostic accuracy is confirmed via internal controls, duplicate testing, and concordance studies with known reference standards. Clinical correlation is mandatory: a PGT result must be interpreted alongside parental karyotypes, carrier status, family history, and pretest genetic counseling—not isolated laboratory values.

Differential diagnosis is inapplicable to PGT itself, as it is not a disease entity. However, clinicians must differentiate between true embryonic aneuploidy versus technical artifacts (e.g., ADO, contamination, mosaicism misclassification) when interpreting PGT-A reports. For PGT-M, differential considerations include pseudodominant inheritance patterns, de novo variants not present in parental blood, and phenocopies caused by environmental or epigenetic factors unrelated to the targeted mutation. Clinically, symptoms prompting referral for PGT—such as recurrent pregnancy loss (≥2 losses), repeated IVF implantation failure (≥3 euploid transfers), or known parental balanced translocation—must be distinguished from other etiologies: antiphospholipid syndrome, thrombophilias, chronic endometritis, uterine anomalies, or sperm DNA fragmentation. Likewise, a patient presenting with anxiety or fatigue during PGT treatment requires evaluation for underlying depression, thyroid dysfunction, or sleep disorders—not attribution to PGT. Misattribution of nonspecific symptoms to PGT risks delaying appropriate diagnosis and management of comorbid medical or psychiatric conditions.

In summary, PGT is a risk-mitigating reproductive technology—not a pathological process. Its value lies in reducing the likelihood of transferring embryos with lethal or severely debilitating genetic conditions, thereby improving cumulative live birth rates per initiated cycle and decreasing miscarriage risk. Patient education must emphasize that symptomatology arises solely from adjunctive fertility interventions, not genetic analysis. Rigorous laboratory quality assurance, multidisciplinary genetic counseling, and individualized clinical integration remain essential to ethical, effective PGT implementation.

Preimplantation Genetic Testing (PGT) is an advanced assisted reproductive technology (ART) performed during in vitro fertilization (IVF) to analyze embryonic genetic material prior to uterine transfer. PGT encompasses three primary modalities: PGT-A (aneuploidy screening), PGT-M (monogenic/single-gene disorder testing), and PGT-SR (structural rearrangements). It is indicated for couples with recurrent pregnancy loss, repeated IVF implantation failure, advanced maternal age (≥35 years), known carrier status for autosomal recessive or X-linked conditions, balanced chromosomal rearrangements, or a prior pregnancy affected by a genetic disorder. As a core service within the Department of Reproductive Medicine, PGT is not a standalone treatment but an integrated diagnostic enhancement to IVF—requiring coordinated multidisciplinary input from reproductive endocrinologists, clinical embryologists, molecular geneticists, and genetic counselors.

Conservative management precedes and supports PGT implementation. This includes comprehensive pre-cycle evaluation: karyotyping of both partners, carrier screening via expanded genomic panels (e.g., 500+ gene panels), ovarian reserve assessment (AMH, AFC, FSH), semen analysis with DNA fragmentation testing, and uterine cavity evaluation (saline infusion sonohysterography or hysteroscopy). Lifestyle optimization is emphasized—smoking cessation, alcohol abstinence, BMI normalization (18.5–24.9 kg/m²), folic acid (400–800 µg/day) and vitamin D supplementation, and stress reduction through cognitive behavioral therapy or mindfulness-based interventions. For patients with mild male factor infertility or borderline ovarian reserve, expectant management with timed intercourse or intrauterine insemination (IUI) may be trialed—but only if genetic risk is low and prognosis remains favorable; PGT is not deferred in high-risk scenarios due to unacceptable risks of transmitting serious monogenic disease or sustaining recurrent aneuploid losses.

Pharmacologic intervention centers on controlled ovarian stimulation (COS) protocols tailored to individual response profiles. Gonadotropin-releasing hormone (GnRH) antagonist regimens are preferred for most patients due to lower risk of premature luteinization and flexibility in trigger timing. Recombinant FSH (e.g., follitropin alfa/beta) ± low-dose LH is titrated based on serial transvaginal ultrasound and estradiol monitoring. Final oocyte maturation is induced with either a GnRH agonist (e.g., leuprolide acetate) in antagonist cycles or recombinant hCG (e.g., chorionic gonadotropin alfa) when appropriate. Luteal phase support includes vaginal micronized progesterone (600–800 mg/day) ± oral dydrogesterone, initiated on the day of oocyte retrieval and continued until pregnancy test confirmation—and extended through week 10 in PGT-conceived pregnancies given the higher baseline risk of luteal insufficiency in freeze-all cycles. Adjunctive medications such as low-dose aspirin (75–100 mg/day) or intravenous immunoglobulin (IVIG) are not evidence-based for routine PGT use and are reserved for research protocols or highly selected cases with documented immune dysregulation.

Surgical treatment is ancillary but critical for optimal PGT outcomes. Hysteroscopic resection of submucosal fibroids (>2 cm), endometrial polyps, or intrauterine adhesions is performed prior to embryo transfer to normalize endometrial receptivity. Laparoscopic evaluation and treatment of moderate-to-severe endometriosis (ASRM Stage III–IV) or hydrosalpinges—via salpingectomy or proximal tubal occlusion—is recommended before PGT-IVF, as these conditions impair implantation and increase miscarriage risk independent of embryo genetics. Varicocelectomy may be offered to men with clinical varicocele and elevated sperm DNA fragmentation (>30%), though its impact on PGT-derived euploid blastocyst rates remains under investigation. All surgical interventions follow strict perioperative antimicrobial prophylaxis and are scheduled to allow ≥3 months for endometrial recovery prior to COS initiation.

China offers distinct advantages in PGT delivery. First, regulatory oversight by the National Health Commission ensures standardized laboratory accreditation (e.g., CAP/CLIA-equivalent certification for >95% Tier-1 ART centers), rigorous validation of next-generation sequencing (NGS) platforms, and mandatory external quality assessment. Second, China’s large-scale patient volume enables rapid protocol refinement—leading to industry-leading blastocyst biopsy success rates (>98%) and concordance between trophectoderm and inner cell mass (>97%). Third, cost-effectiveness is notable: comprehensive PGT-A with NGS costs approximately USD $2,200–$3,500 per cycle (vs. $4,000–$7,000 in the US/EU), inclusive of biopsy, sequencing, bioinformatic analysis, and reporting—all without compromising analytical sensitivity (<10% mosaicism detection threshold). Fourth, integration with national electronic health records facilitates longitudinal tracking of PGT-conceived children, contributing robust real-world data on pediatric outcomes. Finally, China’s centralized ART registry enables timely epidemiological surveillance—supporting evidence-based updates to PGT indications and technical standards.

Post-PGT recovery focuses on physiological stabilization and psychological continuity. Patients undergoing freeze-all cycles (standard for PGT) require endometrial preparation with sequential estrogen priming (2–3 weeks) followed by progesterone initiation 5–6 days prior to euploid blastocyst transfer. Strict adherence to medication timing and vaginal administration technique is reinforced. Post-transfer, patients are advised to avoid heavy lifting (>10 kg), vigorous exercise, hot tubs, and intercourse for 10 days—but routine ambulation and desk-based work are encouraged. Psychological support is integral: structured counseling addresses anxiety related to mosaic result interpretation, decision-making regarding embryo disposition, and adjustment to prolonged treatment timelines. Nutritional guidance emphasizes anti-inflammatory foods (omega-3-rich fish, leafy greens, berries), adequate hydration (2–2.5 L/day), and avoidance of ultra-processed sugars. Follow-up includes serum β-hCG testing 10 days post-transfer, transvaginal ultrasound at 6–7 weeks to confirm viability and gestational age, and referral to maternal-fetal medicine for first-trimester aneuploidy screening (NIPT) and detailed anatomy scan at 18–22 weeks—even after PGT, given residual limitations in detecting low-level mosaicism, uniparental disomy, or de novo CNVs. Long-term follow-up includes pediatric developmental assessments at 12 and 24 months, coordinated through regional birth cohort programs. Ultimately, PGT represents not merely a technical procedure but a precision reproductive strategy—one that demands scientific rigor, ethical transparency, and compassionate continuity of care.